The reimbursement review for the acute myeloid leukemia treatment Xospata is making way to overcome the existing restriction that limits the reimbursement to 4 cycles.

According to industry sources, Xospata (gilteritinib), Astellas Korea’s new drug for patients with relapsed or refractory acute myeloid leukemia (AML) with an FLT3 mutation will be presented for review at the Health Insurance Review and Assessment Service’s Drug Reimbursement Evaluation Committee meeting on July 1st.

The drug’s reimbursement application is seemingly making relatively quick progress after passing the Cancer Disease Deliberation Committee in May. However, since Xospata was waived the pharmacoeconomic eva